MapLight Therapeutics Inc. (MPLT)
MPLT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | MPLT on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2025 |
| SEC CIK | 0001770069 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials
Recent IPO: no annual report filed yet.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-13 |
| Cash and burn | $71.6M cash; operating cash flow -$43.7M a quarter. | Report 2026-06-30 |
| Shares outstanding | 46,377,832 (2026-07-31). | Cover page 2026-07-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | RSM US LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-04-06 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $174.9M, sold $29.2M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | Not filed | -$60.2M | -$44.9M | $71.6M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$60.7M | -$51.2M | $55.7M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | Not filed | -$79.5M | -$46.8M | $46.7M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2025 2025-09-30 | Not filed | -$29.4M | -$31.8M | $64.1M | No debt tags | Needs four quarters | 10-Q 2025-12-04 |
| Q2 2025 2025-06-30 | Not filed | -$29.8M | -$34.0M | Not filed | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2025 2025-03-31 | Not filed | -$22.3M | -$25.6M | Not filed | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | Not filed | -$21.2M | -$21.5M | $38.3M | No debt tags | Needs four quarters | 10-K 2026-03-26 |
| Q3 2024 2024-09-30 | Not filed | -$19.0M | Not filed | Not filed | No debt tags | Needs four quarters | 10-Q 2025-12-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-11-16 |
| Latest annual report | 10-K | 2026-03-26 |
| Latest quarterly / interim | 10-Q | 2026-11-16 |
| Latest current report | 8-K | 2026-11-16 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 216 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.6% |
| 1 month | -7.9% |
| 3 months | -37.4% |
| Year to date | -58.7% |
| 1 year | -49.2% |
| From 52-week high | -81.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| DMAC | DiaMedica Therapeutics Inc. | $8.33 | -5.23% | $449.5M |
| ARVN | Arvinas Inc. | $6.77 | -0.73% | $443.3M |
| OVID | Ovid Therapeutics Inc. | $2.40 | -5.51% | $453.0M |
| EOLS | Evolus Inc. | $6.63 | -4.74% | $438.8M |
| ASMB | Assembly Biosciences Inc. | $21.29 | +0.80% | $436.0M |
| BLSM | BlossomHill Therapeutics Inc. | $13.65 | -2.64% | $433.9M |
| CTMX | CytomX Therapeutics Inc. | $1.99 | -2.70% | $432.7M |
| KMDA | Kamada Ltd. | $8.11 | +0.25% | $468.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier